Log In
Print
BCIQ
Print
Print this Print this
 

quizartinib (AC220)

  Manage Alerts
Collapse Summary General Information
Company Ambit Biosciences Corp.
DescriptionOral small molecule FMS-like tyrosine kinase 3 (FLT3; CD135) inhibitor
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor
Latest Stage of DevelopmentPhase II
IndicationAcute myelogenous leukemia (AML)
Partner

Astellas Pharma Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today